Suppr超能文献

通过免疫分析对抗凝类肝素进行表征。

Characterization of anticoagulant heparinoids by immunoprofiling.

作者信息

Wijnhoven Tessa J, van de Westerlo Els M, Smits Nicole C, Lensen Joost F, Rops Angelique L, van der Vlag Johan, Berden Jo H, van den Heuvel Lambert P, van Kuppevelt Toin H

机构信息

Department of Matrix Biochemistry, Nijmegen Centre for Molecular Life Sciences, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands.

出版信息

Glycoconj J. 2008 Feb;25(2):177-85. doi: 10.1007/s10719-007-9070-z. Epub 2007 Oct 2.

Abstract

Heparinoids are used in the clinic as anticoagulants. A specific pentasaccharide in heparinoids activates antithrombin III, resulting in inactivation of factor Xa and-when additional saccharides are present-inactivation of factor IIa. Structural and functional analysis of the heterogeneous heparinoids generally requires advanced equipment, is time consuming, and needs (extensive) sample preparation. In this study, a novel and fast method for the characterization of heparinoids is introduced based on reactivity with nine unique anti-heparin antibodies. Eight heparinoids were biochemically analyzed by electrophoresis and their reactivity with domain-specific anti-heparin antibodies was established by ELISA. Each heparinoid displayed a distinct immunoprofile matching its structural characteristics. The immunoprofile could also be linked to biological characteristics, such as the anti-Xa/anti-IIa ratio, which was reflected by reactivity of the heparinoids with antibodies HS4C3 (indicative for 3-O-sulfates) and HS4E4 (indicative for domains allowing anti-factor IIa activity). In addition, the immunoprofile could be indicative for heparinoid-induced side-effects, such as heparin-induced thrombocytopenia, as illustrated by reactivity with antibody NS4F5, which defines a very high sulfated domain. In conclusion, immunoprofiling provides a novel, fast, and simple methodology for the characterization of heparinoids, and allows high-throughput screening of (new) heparinoids for defined structural and biological characteristics.

摘要

类肝素在临床上用作抗凝剂。类肝素中的一种特定五糖可激活抗凝血酶III,导致Xa因子失活,并且在存在额外糖类时导致IIa因子失活。对异质性类肝素进行结构和功能分析通常需要先进的设备,耗时且需要(大量的)样品制备。在本研究中,基于与九种独特的抗肝素抗体的反应性,引入了一种用于类肝素表征的新颖快速方法。通过电泳对八种类肝素进行生化分析,并通过ELISA确定它们与结构域特异性抗肝素抗体的反应性。每种类肝素都显示出与其结构特征相匹配的独特免疫图谱。该免疫图谱还可以与生物学特性相关联,例如抗Xa/抗IIa比率,这通过类肝素与抗体HS4C3(指示3-O-硫酸盐)和HS4E4(指示允许抗IIa因子活性的结构域)的反应性反映出来。此外,该免疫图谱可能指示类肝素诱导的副作用,例如肝素诱导的血小板减少症,如与定义非常高硫酸化结构域的抗体NS4F5的反应性所示。总之,免疫图谱分析为类肝素的表征提供了一种新颖、快速且简单的方法,并允许对(新的)类肝素进行高通量筛选以确定其结构和生物学特性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e601/2234449/37b9c7d21d69/10719_2007_9070_Fig1_HTML.jpg

相似文献

1
Characterization of anticoagulant heparinoids by immunoprofiling.
Glycoconj J. 2008 Feb;25(2):177-85. doi: 10.1007/s10719-007-9070-z. Epub 2007 Oct 2.
2
Heparinoid Complex-Based Heparin-Binding Cytokines and Cell Delivery Carriers.
Molecules. 2019 Dec 17;24(24):4630. doi: 10.3390/molecules24244630.
3
Heparinoids Danaparoid and Sulodexide as clinically used drugs.
Prog Mol Biol Transl Sci. 2019;163:55-74. doi: 10.1016/bs.pmbts.2019.02.005. Epub 2019 Mar 21.
7
Allergy to heparins and anticoagulants with a similar pharmacological profile: an update.
Blood Coagul Fibrinolysis. 2006 Nov;17(8):605-13. doi: 10.1097/01.mbc.0000198992.18384.5a.
8
Anticoagulant and antiprotease activities of a heparinoid sulfated glucoside-bearing polymer.
J Biomater Sci Polym Ed. 1998;9(9):973-84. doi: 10.1163/156856298x00280.
9
Delayed-type hypersensitivity to low molecular weight heparins and heparinoids: cross-reactivity does not depend on molecular weight.
Br J Dermatol. 2007 Sep;157(3):514-7. doi: 10.1111/j.1365-2133.2007.08007.x. Epub 2007 Jun 15.

引用本文的文献

1
Imaging Glycosaminoglycan Modification Patterns In Vivo.
Methods Mol Biol. 2022;2303:539-557. doi: 10.1007/978-1-0716-1398-6_42.
2
Role of the Extracellular Matrix in Alzheimer's Disease.
Front Aging Neurosci. 2021 Aug 27;13:707466. doi: 10.3389/fnagi.2021.707466. eCollection 2021.
3
Conservation of anatomically restricted glycosaminoglycan structures in divergent nematode species.
Glycobiology. 2016 Aug;26(8):862-870. doi: 10.1093/glycob/cww037. Epub 2016 Mar 13.
5
Characterization of the interaction between the chlamydial adhesin OmcB and the human host cell.
J Bacteriol. 2013 Dec;195(23):5323-33. doi: 10.1128/JB.00780-13. Epub 2013 Sep 20.
6
Immobilization of heparan sulfate on electrospun meshes to support embryonic stem cell culture and differentiation.
J Biol Chem. 2013 Feb 22;288(8):5530-8. doi: 10.1074/jbc.M112.423012. Epub 2012 Dec 12.
8
10
SPECT imaging of peripheral amyloid in mice by targeting hyper-sulfated heparan sulfate proteoglycans with specific scFv antibodies.
Nucl Med Biol. 2012 Jan;39(1):65-75. doi: 10.1016/j.nucmedbio.2011.06.007. Epub 2011 Sep 29.

本文引用的文献

1
Characterization of anti-heparan sulfate phage display antibodies AO4B08 and HS4E4.
J Biol Chem. 2007 Jul 20;282(29):21032-42. doi: 10.1074/jbc.M702073200. Epub 2007 May 21.
2
3
Guidelines on the use and monitoring of heparin.
Br J Haematol. 2006 Apr;133(1):19-34. doi: 10.1111/j.1365-2141.2005.05953.x.
4
3-O-sulfated oligosaccharide structures are recognized by anti-heparan sulfate antibody HS4C3.
J Biol Chem. 2006 Feb 24;281(8):4654-62. doi: 10.1074/jbc.M506357200. Epub 2005 Dec 22.
6
Generic low-molecular-weight heparins: some practical considerations.
Semin Thromb Hemost. 2004 Dec;30(6):703-13. doi: 10.1055/s-2004-861513.
7
A synthetic antithrombin III binding pentasaccharide is now a drug! What comes next?
Angew Chem Int Ed Engl. 2004 Jun 14;43(24):3118-33. doi: 10.1002/anie.200300640.
8
Antitumor and antimetastatic effect of warfarin and heparins.
Biomed Pharmacother. 2004 May;58(4):213-9. doi: 10.1016/j.biopha.2003.11.007.
9
Heparin-induced thrombocytopenia.
J Thromb Haemost. 2003 Jul;1(7):1471-8. doi: 10.1046/j.1538-7836.2003.00270.x.
10
Fondaparinux: a new antithrombotic agent.
Clin Ther. 2002 Nov;24(11):1757-69; discussion 1719. doi: 10.1016/s0149-2918(02)80077-7.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验